Nanomedicine: Nanotechnology, Biology and Medicine
Volume 6, Issue 3 , Pages 478-485 , June 2010

Preparation and in vitro evaluation of actively targetable nanoparticles for SN-38 delivery against HT-29 cell lines

  • Pedram Ebrahimnejad, PharmD

      Affiliations

    • Novel Drug Delivery Systems Lab, Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
    • Biotechnology Research Centre, Faculty of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
    • ,
  • Rassoul Dinarvand, PharmD, PhD

      Affiliations

    • Novel Drug Delivery Systems Lab, Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
    • Medical Nanotechnology Research Centre, Tehran University of Medical Sciences, Tehran, Iran
    • Corresponding Author InformationCorresponding author: Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran PO Box 14155-6451, Iran.
    • ,
  • Abolghasem Sajadi, PharmD, PhD

      Affiliations

    • Pharmacological Research Centre of Medicinal Plants, Faculty of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
    • ,
  • Mahmoud Reza Jaafari, PharmD, PhD

      Affiliations

    • Biotechnology Research Centre, Faculty of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
    • ,
  • Ali Reza Nomani, PharmD

      Affiliations

    • Novel Drug Delivery Systems Lab, Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
    • Pharmacology Research Lab, Department of Toxicology-Pharmacology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
    • ,
  • Ebrahim Azizi, PharmD, PhD

      Affiliations

    • Medical Nanotechnology Research Centre, Tehran University of Medical Sciences, Tehran, Iran
    • Pharmacology Research Lab, Department of Toxicology-Pharmacology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
    • ,
  • Mazda Rad-Malekshahi, PharmD

      Affiliations

    • Novel Drug Delivery Systems Lab, Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
    • ,
  • Fatemeh Atyabi, PharmD, PhD

      Affiliations

    • Novel Drug Delivery Systems Lab, Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
    • Medical Nanotechnology Research Centre, Tehran University of Medical Sciences, Tehran, Iran

Received 20 February 2009 ,Accepted 2 October 2009.

References 

  1. Kunii R, Onishi H, Machida Y. Preparation and antitumor characteristics of PLA/(PEG-PPG-PEG) nanoparticles loaded with camptothecin. Eur J Pharm Biopharm. 2007;67:9–17
  2. Zhang JA, Xuan T, Parmar M, Ma L, Ugwu S, Ali S, et al. Development and characterization of a novel liposome-based formulation of SN-38. Int J Pharm. 2004;270:93–107
  3. Kolhatkar RB, Swaan P, Ghandehari H. Potential oral delivery of 7-ethyl-10-hydroxy-camptothecin (SN-38) using poly(amidoamine) dendrimers. Pharm Res. 2008;25:1723–1729
  4. Ebrahimnejad F, Dinarvand R, Sajadi SA, Atyabi F, Ramezani F, Jafari MR. Preparation and characterization of poly lactide-co-glycolide nanoparticles of SN-38.. PDA J Pharm Sci Tech. 2009;(in press)
  5. Bodurka DC, Levenback C, Wolf JK, Gano J, Wharton JT, Kavanagh JJ, et al. Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. J Clin Oncol. 2003;21:291–297
  6. Koizumi F, Kitagawa M, Negishi T, Onda T, Matsumoto S, Hamaguchi T, et al. Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors. Cancer Res. 2006;66:10048–10056
  7. Bawarski WE, Chidlowsky E, Bharali DJ, Mousa SA. Emerging nanopharmaceuticals. Nanomedicine: NBM. 2008;4:273–282
  8. De Verdiere AC, Dubernet C, Nemati F, Poupon MF, Puisieux F, Couvreur P. Uptake of doxorubicin from loaded nanoparticles in multidrug-resistant leukemic murine cells. Cancer Chem Pharmacol. 1994;33:504–508
  9. Koo OM, Rubinstein I, Onyuksel H. Role of nanotechnology in targeted drug delivery and imaging: a concise review. Nanomedicine: NBM. 2005;1:193–212
  10. Zhang Z, Huey Lee S, Feng SS. Folate-decorated poly(lactide-co-glycolide)-vitamin E TPGS nanoparticles for targeted drug delivery. Biomaterials. 2007;28:1889–1899
  11. Reddy JA, Low PS. Enhanced folate receptor mediated gene therapy using a novel pH-sensitive lipid formulation. J Controlled Release. 2000;64:27–37
  12. Lu Y, Low PS. Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors. Cancer Immunol Immunother. 2002;51:153–162
  13. Yoo HS, Park TG. Biodegradable polymeric micelles composed of doxorubicin conjugated PLGA-PEG block copolymer. J Controlled Release. 2001;70:63–70
  14. Cummings J, McArdle CS. Studies on the in vivo disposition of adriamycin in human tumours which exhibit different responses to the drug. Br J Cancer. 1986;53:835–838
  15. Sudimack J, Lee RJ. Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev. 2000;41:147–162
  16. Esmaeili F, Ghahremani MH, Ostad SN, Atyabi F, Seyedabadi M, Malekshahi MR, et al. Folate-receptor-targeted delivery of docetaxel nanoparticles prepared by PLGA-PEG-folate conjugate. J Drug Target. 2008;16(5):415–423
  17. Kim SH, Jeong JH, Chun KW, Park TG. Target-specific cellular uptake of PLGA nanoparticles coated with poly(L-lysine)-poly(ethylene glycol)-folate conjugate. Langmuir. 2005;21:8852–8857
  18. De Nonancourt-Didion M, Gueant JL, Adjalla C, Chery C, Hatier R, Namour F. Overexpression of folate binding protein α is one of the mechanism explaining the adaptation of HT29 cells to high concentration of methotrexate. Cancer Lett. 2001;171:139–145
  19. Pellis L, Dommels Y, Venema D, et al. High folic acid increases cell turnover and lowers differentiation and iron content in human HT29 colon cancer cells. Br J Nutr. 2008;99:703–708
  20. Yoo HS, Park TG. Folate receptor targeted biodegradable polymeric doxorubicin micelles. J Controlled Release. 2004;96:273–283
  21. Lee RJ, Low PS. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochimica Et Biophysica Acta - Biomembranes. 1995;1233:134–144
  22. Esmaeili F, Hosseini-Nasr M, Rad-Malekshahi M, Samadi N, Atyabi F, Dinarvand R. Preparation and antibacterial activity evaluation of rifampicin-loaded poly lactide-co-glycolide nanoparticles. Nanomedicine: NBM. 2007;3:161–167
  23. Ebrahimnejad P, Dinarvand R, Sajadi SA, Jafari MR, Movaghari F, Atyabi F. Development and validation of an ion-pair HPLC chropmatography for simultaneous determination of lactone and carboxylate forms of SN-38 in nanoparticles. J Food Drug Anal. 2009;17:246–256
  24. Zhang Z, Feng SS. The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly(lactide)-tocopheryl polyethylene glycol succinate nanoparticles. Biomaterials. 2006;27:4025–4033
  25. Bharali DJ, Pradhan V, Elkin G, Qi W, Hutson A, Mousa SA, et al. Novel nanoparticles for the delivery of recombinant hepatitis B vaccine. Nanomedicine: NBM. 2008;4:311–317
  26. Yadav AK, Mishra P, Mishra AK, Mishra P, Jain S, Agrawal GP. Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin. Nanomedicine: NBM. 2007;3:246–257
  27. Muller C, Brulmeier M, Schubiger PA, Schibli R. Effects of antifolate drugs on the cellular uptake of radiofolates in vitro and in vivo. J Nucl Med. 2006;47:2057–2064
  28. Dong Y, Feng SS. Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs. Biomaterials. 2004;25:2843–2849
  29. Magenheim B, Levy MY, Benita S. A new in vitro technique for the evaluation of drug release profile from colloidal carriers—ultrafiltration technique at low pressure. Int J Pharm. 1993;94:115–123
  30. Panyam J, Labhasetwar V. Dynamics of endocytosis and exocytosis of poly(D,L-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells. Pharm Res. 2003;20:212–220
  31. Gabizon AA. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res. 1992;52:891–896
  32. Adcock IM, Ito K. Glucocorticoid pathways in chronic obstructive pulmonary disease therapy. Proc Am Thor Soc. 2005;2:313–319
  33. Zhao J, Kim JE, Reed E, Li QQ. Molecular mechanism of antitumor activity of taxanes in lung cancer. Int J Oncol. 2005;27:247–256
  34. Zhang L, Yang M, Wang Q, Li Y, Guo R, Jiang X, et al. 10-Hydroxycamptothecin loaded nanoparticles: preparation and antitumor activity in mice. J Controlled Release. 2007;119:153–162

 This work was supported by Medical Nanotechnology Research Center, Tehran University of Medical Sciences, and the Special Office for Nanotechnology Development.

PII: S1549-9634(09)00191-9

doi: 10.1016/j.nano.2009.10.003

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 6, Issue 3 , Pages 478-485 , June 2010

Article Tools

* Image Usage & Resolution